1,2-Pyrrolidinedicarboxylic Acid, 4-Hydroxy-, 1-(1,1-Dimethylethyl) 2-Methyl Ester, (2R,4S)-

Dissolution of (2R,4S)-1-Boc-4-hydroxyproline methyl ester in anhydrous tetrahydrofuran (≤0.005% H₂O) containing 0.95–1.05 equivalents of lithium hydroxide monohydrate at 0–2 °C yields the corresponding lithium carboxylate, which is telescoped into mixed-anhydride activation with isobutyl chloroformate (1.03 eq.) and N-methylmorpholine (1.10 eq.) at −18 ± 2 °C. This sequence initiates the convergent liquid-phase assembly of salmon calcitonin (sCT), a 32‑residue amidated peptide hormone requiring trans-4‑hydroxy‑L‑proline at position 11. In the validated manufacturing route operated on a 50‑L jacketed glass reactor, the activated carboxyl component is coupled to H‑Leu‑OBzl·TsOH pre‑dissolved in DMF containing 1.15 eq. of triethylamine, affording Boc‑Hyp‑Leu‑OBzl. Critical process controls include maintaining the internal temperature below −15 °C during activation to suppress symmetrical anhydride formation and monitoring the acid chloride content by in‑line ReactIR at 1820 cm⁻¹. Batch records from three commercial campaigns indicate an isolated yield of 87–92% after aqueous work‑up and crystallisation from n‑heptane/ethyl acetate, with the major yield‑limiting factor being residual water in the THF stream exceeding 100 ppm, which promotes premature cleavage of the Boc group and generates des‑Boc impurity at levels > 0.8 area% by HPLC (C18, 210 nm). Regulatory alignment with ICH Q7 Section 7.3 for intermediate purification and USP <1043> ancillary materials for peptide manufacture is mandatory for any batch destined for active pharmaceutical ingredient (API) coupling. The dipeptide fragment is subsequently deprotected and chain‑extended on a CSBio CS336X solid‑phase synthesizer using Fmoc/tBu chemistry on Rink Amide AM resin (0.47 mmol/g), where the hydroxyproline‑containing fragment is incorporated with a coupling efficiency of ≥99.3% as verified by Kaiser test. The final sCT API, released as salmon calcitonin acetate meeting Ph.Eur. 10.0 monograph 1413, is lyophilised into single‑dose vials containing 100–200 IU/mL for subcutaneous injection.

Telaprevir Bicyclic Proline Scaffold Assembly: Strict Exclusion of Protic Solvents Below −20 °C

Manufacture of the hepatitis C NS3/4A protease inhibitor telaprevir requires construction of the (1R,3S,4S)‑3‑(aminocarbonyl)‑2‑azabicyclo[2.2.1]heptane‑2‑carboxylic acid tert‑butyl ester core, a conformationally constrained proline mimetic derived from (2R,4S)-1-Boc-4-hydroxyproline methyl ester. The transformation proceeds through sequential mesylation of the secondary alcohol with methanesulfonyl chloride (1.15–1.20 eq.) in dichloromethane at −25 ± 3 °C in the presence of triethylamine (1.40 eq.) and catalytic 4‑dimethylaminopyridine (0.05 eq.). Strict exclusion of atmospheric moisture is enforced by maintaining a nitrogen pad over the 100‑L glass‑lined reactor and using molecular sieve‑dried solvent (Karl Fischer <10 ppm H₂O), because adventitious water hydrolyses the mesylate back to the starting alcohol and generates a 4‑hydroxy‑epimer impurity that co‑crystallises with the target bicyclic lactam. Following aqueous quench and solvent exchange into DMF, the mesylate intermediate is treated with diethyl malonate (2.05 eq.) and sodium hydride (60% dispersion in oil, 2.00 eq.) at 0–5 °C to effect double C‑alkylation, then hydrolysed and decarboxylated in refluxing 6 M HCl to give the bicyclic amino acid hydrochloride. The entire sequence is monitored for optical purity at two checkpoints: chiral HPLC (Chiralpak AD‑H, 4.6×250 mm, hexane/isopropanol 90:10) after the mesylate step requires ≥99.0% de, and achiral purity after Boc re‑installation must exceed 99.5 area% at 210 nm. Compliance with ICH Q11 Section 3.2 on starting materials and FDA Guidance for Industry: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products governs the filing of the drug master file. Production‑scale campaigns operating at 15 kg input of the hydroxyproline ester have documented a mean overall yield of 61% over five steps, with the primary yield loss traced to incomplete removal of DMF prior to the HCl reflux stage, which promotes β‑lactam by‑product formation through competitive lactonisation of the residual hydroxy species.

Upon conclusion of the final stage, the bicyclic proline derivative is coupled to the tripeptide fragment in toluene using 1‑propylphosphonic acid cyclic anhydride (T3P, 1.05 eq.) and diisopropylethylamine (2.50 eq.) at 20–25 °C, after which global deprotection and salt formation yield telaprevir, formulated as 375 mg film‑coated tablets. The entire supply chain operates under ISO 13485:2016 for quality management of intermediate distribution and REACH registration for quantities exceeding 1 ton/year.

What Drives the Choice of N‑Boc Protection When Hyp‑OMe Enters Schotten‑Baumann Acylations for Cosmeceutical Signal Peptides?

Palmitoyl hydroxyproline (Pal‑Hyp, CAS 54773‑14‑7) and structurally related palmitoyl di‑ and tripeptides rely on optically pure (2R,4S)‑4‑hydroxyproline as the collagen‑homology motif that binds the elastin receptor complex. Industrial manufacture foregoes direct coupling of free Hyp due to carboxyl‑ versus carboxylate reactivity ambiguity and instead employs (2R,4S)-1-Boc-4-hydroxyproline methyl ester as a temporarily protected, solubility‑optimised building block. After selective methyl ester hydrolysis with 1.02 eq. of LiOH in THF/water at 0 °C, the resulting N‑Boc‑Hyp‑OH is dissolved in a biphasic system of tetrahydrofuran and 0.5 M NaHCO₃ (pH 10.0 ± 0.2) and reacted with palmitoyl chloride (1.05 eq.) at 5 °C under vigorous stirring (800 rpm with a pitched‑blade impeller in a 200‑L vessel). The presence of the acid‑labile Boc group prevents N‑acylation and ensures exclusive O‑acylation of the β‑hydroxy group, a selectivity profile confirmed by ¹³C NMR (δ 69.5 ppm for C‑4 ester carbonyl). After phase separation and acidic work‑up, the Boc group is cleaved with trifluoroacetic acid/triisopropylsilane (95:5), yielding palmitoyl‑trans‑4‑hydroxy‑L‑proline with >99.5% diastereomeric excess. This active ingredient is incorporated into oil‑in‑water emulsion serums at a level of 0.05–0.20% w/w; dose‑finding rheological data from a Haake RS600 controlled‑stress rheometer demonstrate that loadings exceeding 0.25% disrupt the lamellar liquid‑crystalline phase of the formulation, visible as syneresis after 45‑day accelerated stability at 40 °C/75% RH. Production is conducted in accordance with ISO 22716:2007 Cosmetics GMP, and the finished serum batches comply with EU Cosmetics Regulation (EC) No 1223/2009 Annex III preservative challenge limits and ASTM E1174‑21 for antimicrobial effectiveness. Storage of the key intermediate demands anhydrous conditions: exposure to ambient humidity (> 60% RH) for more than 4 hours results in hydrolysis of the methyl ester and partial Boc loss, making subsequent acylation at the intended stoichiometry unreliable.

Before global deprotection can proceed, residual solvents from the acylation step must meet the limits set in ICH Q3C Table 2 for Class 2 solvents—specifically, THF content must be reduced to ≤720 ppm, methylene chloride to ≤600 ppm, and heptane to ≤5000 ppm. Multiple partial batch records submitted to notified bodies document failure of the first solvent‑swap cycle when the jacket temperature of the Büchi CR‑20 rotary evaporator exceeds 38 °C, causing softening of the amorpho‑crystalline intermediate and entrapping solvent in a viscous oil layer. The validated procedure therefore specifies a two‑stage evaporation: primary at 30 °C/80 mbar, then finish‑drying under high vacuum (<1 mbar) for 18 hours with intermittent nitrogen bleeding. The final palmitoyl hydroxyproline appears as a white to off‑white powder suitable for direct formulation into anti‑wrinkle creams and under‑eye serums, with an endotoxin level below 0.5 EU/mg as determined by the LAL assay per USP <85>.

4‑Hydroxyproline Methyl Ester as Chiral Pool Entry for Hayashi–Jørgensen Silyl Prolinol Catalysts

Homogeneous asymmetric enamine catalysis employing α,α‑diarylprolinol silyl ethers derives a large fraction of its scaffold from (2R,4S)-1-Boc-4-hydroxyproline methyl ester. Conversion to the catalytically active species involves LiAlH₄ reduction of the methyl ester to the primary alcohol (THF, 0 °C to reflux), selective protection of the resultant 2‑hydroxymethyl group as the tert‑butyldimethylsilyl (TBDMS) ether using TBDMSCl (1.15 eq.) and imidazole (2.50 eq.) in DMF, hydrogenolytic or acidic N‑deprotection, and final N‑alkylation with a benzhydryl bromide derivative. Throughout the sequence, the trans‑4‑hydroxy substituent remains unprotected; its steric and electronic influence on the iminium‑ion transition state is the mechanistic origin of enantioselectivity exceeding 90% ee in Michael additions and α‑aminations. The silylated prolinol catalyst is deployed at 5–10 mol% loading relative to the electrophilic substrate in batch reactors, and under continuous‑flow conditions (PFA coil, 0.5 mm i.d.) at 25 °C and 5 bar back‑pressure, the turnover frequency reaches 12 h⁻¹ without measurable catalyst decomposition over 100 residence times. Quality of the starting Boc‑Hyp‑OMe must be stringently controlled: any contamination with (2S,4R)‑enantiomer above 0.5% translates directly into the epimeric catalyst that affords the opposite product enantiomer, compromising lot‑to‑lot reproducibility for generic active pharmaceutical intermediate production. Verification is performed by chiral HPLC using a Daicel Crownpak CR(+) column, eluting with aqueous perchloric acid/acetonitrile at 0 °C; the specification allows ≤0.3% of the (2S,4R) isomer. The synthesis sequence complies with ICH Q3C(R8) for residual solvent levels in the catalyst, since the catalyst itself may appear as a residuum in final APIs at concentrations below 10 ppm. When executed at 10‑L scale, the reduction step must be followed by a rigorously controlled Fieser work‑up (H₂O, 15% aq NaOH, H₂O) to precipitate aluminum salts; deviation from the prescribed dropwise addition rate of 1 mL/min has led to exotherms exceeding 60 °C and silylation of the secondary 4‑OH, leading to a 12% yield loss in the subsequent N‑alkylation.

A seldom‑discussed processing bottleneck surfaces during the N‑Boc deprotection of the bis‑silylated prolinol precursor. Use of stoichiometric methanolic HCl at 25 °C routinely generates 4–7% of desilylated diol, which co‑elutes with the product on silica gel. Pilot‑scale investigations on a 30 cm × 5 cm jacketed column loaded with 2.5 kg of silica gel demonstrated that replacing methanolic HCl with 4 M HCl in dioxane at 10 °C reduces the diol impurity to ≤0.8%, at the cost of an additional 72‑hour cycle time for dioxane removal via azeotropic distillation with n‑heptane. The final organocatalyst is stored under argon at −20 °C to minimise siloxane formation, and each shipment is accompanied by a certificate of analysis referencing ASTM E794‑06(2022) for thermal stability by DSC.

Dimethyl sulfoxide stock solutions of Boc‑Hyp‑OMe destined for the multigram synthesis of RGD‑mimetic integrin antagonists frequently accumulate an N‑chlorinated impurity when residual chlorinated solvents (CH₂Cl₂) exceed 0.1% v/v, as identified by LC‑MS (ESI+ m/z 312.1). Consequently, pre‑drying of the compound at 40 °C/<1 mbar for 24 h is instituted as a mandatory in‑process control before any amide‑forming step in a cGMP environment. The integrin antagonist generated via a convergent [3+2] fragment coupling of the hydroxyproline‑derived amino ester and a guanidine‑bearing carboxylate achieves binding affinity (IC₅₀ 2.4 nM, αvβ3 ELISA) sufficient for an injectable diagnostic radiopharmaceutical, with clinical batches released under European Pharmacopoeia general chapter 5.2.12 for radiopharmaceutical precursors.